Resources
BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]
M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]
BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]
BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered a growing healthcare epidemic and is associated with significant mortality, morbidity and resource utilization. In the United States, HF is estimated to[…]
BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]
